ESR1 alterations and metastasis in estrogen receptor positive breast cancer

Abstract

Endocrine therapy is essential for the treatment of patients with estrogen receptor positive (ER+) breast cancer, however, resistance and the development of metastatic disease is common. Understanding how ER+ breast cancer metastasizes is critical since the major cause of death in breast cancer is metastasis to distant organs. Results from many studies suggest dysregulation of the estrogen receptor alpha gene (ESR1) contributes to therapeutic resistance and metastatic biology. This review covers both pre-clinical and clinical evidence on the spectrum of ESR1 alterations including amplification, point mutations, and genomic rearrangement events driving treatment resistance and metastatic potential of ER+ breast cancer. Importantly, we describe how these ESR1 alterations may provide therapeutic opportunities to improve outcomes in patients with lethal, metastatic breast cancer.

Keywords

Endocrine therapy resistance / ESR1 fusions / ESR1 mutations / breast cancer / metastasis

References

[1] Harvey JM,Osborne CK.Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer..J Clin Oncol1999;17:1474-81

[2] Joel PB,Lannigan DA.Estradiol and phorbol ester cause phosphorylation of serine 118 in the human estrogen receptor..Mol Endocrinol1995;9:1041-52

[3] Le Goff P,Schodin DJ.Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity..J Biol Chem1994;269:4458-66

[4] Kato S,Masuhiro Y,Uchiyama S.Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase..Science1995;270:1491-4

[5] Zhou W SJ.Links between oestrogen receptor activation and proteolysis: relevance to hormone-regulated cancer therapy..Nat Rev Cancer2014;14:26-38

[6] Zwart W,Rondaij M,Mancini MA.The hinge region of the human estrogen receptor determines functional synergy between AF-1 and AF-2 in the quantitative response to estradiol and tamoxifen..J Cell Sci2010;123:1253-61

[7] Davies C,Gray R.Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials..Lancet2011;378:771-84 PMCID:PMC3163848

[8] Ma CX,Chmielewska I.Mechanisms of aromatase inhibitor resistance..Nat Rev Cancer2015;15:261-75

[9] Osborne CK,Hopp TA,Hilsenbeck SG.Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer..J Natl Cancer Inst2003;95:353-61

[10] Arpino G,Allred DC,Martino S.HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study..Clin Cancer Res2004;10:5670-6

[11] Fan P,Santen RJ.Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells..Cancer Res2007;67:1352-60

[12] Song RX,Zhang Z,Kumar R.The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane..Proc Natl Acad Sci U S A2004;101:2076-81 PMCID:PMC357054

[13] Osborne CK,Dirix LY,Robert J.Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study..Clin Cancer Res2011;17:1147-59 PMCID:PMC3074404

[14] Ellis MJ.The genomic landscape of breast cancer as a therapeutic roadmap..Cancer Discov2013;3:27-34 PMCID:PMC3553590

[15] Sanchez CG,Crowder RJ,Phommaly C.Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer..Breast Cancer Res2011;13:R21 PMCID:PMC3219179

[16] Baselga J,Piccart M,Rugo HS.Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer..N Engl J Med2012;366:520-9 PMCID:PMC5705195

[17] Di Leo A,Lee KS,Lonning PE.Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial..Lancet Oncol2018;19:87-100

[18] André F,Rubovszky G,Loibl S.Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): results of the phase 3 SOLAR-1 trial.2018;Munich, GermanyESMO Congress

[19] Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours..Nature2012;490:61-70 PMCID:PMC3465532

[20] Thangavel C,Ertel A,Aldaz CM.Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer..Endocr Relat Cancer2011;18:333-45 PMCID:PMC3624623

[21] Ma CX,Luo J,Goetz M.NeoPalAna: neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor-positive breast cancer..Clin Cancer Res2017;23:4055-65 PMCID:PMC5555232

[22] Basudan A,Hartmaier RJ,Bahreini A.Frequent ESR1 and CDK pathway copy-number alterations in metastatic breast cancer..Mol Cancer Res2019;17:457-68 PMCID:PMC6359977

[23] Zhang QX,Wolf DM,Fuqua SA.An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer..Cancer Res1997;57:1244-9

[24] Pejerrey SM,Kim JA,Rechoum Y.The impact of ESR1 mutations on the treatment of metastatic breast cancer..Horm Cancer2018;9:215-28

[25] Niu J,Kramer K,Alvarez RH.Incidence and clinical significance of ESR1 mutations in heavily pretreated metastatic breast cancer patients..Onco Targets Ther2015;8:3323-8 PMCID:PMC4648593

[26] Borg A,Sigurdsson H,Ferno M.HER-2/neu amplification predicts poor survival in node-positive breast cancer..Cancer Res1990;50:4332-7

[27] Turner N,Sharpe R,Geyer F.FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer..Cancer Res2010;70:2085-94 PMCID:PMC2832818

[28] Nembrot M,Mordoh J.Estrogen receptor gene amplification is found in some estrogen receptor-positive human breast tumors..Biochem Biophys Res Commun1990;166:601-7

[29] Holst F,Ruiz C,Jehan Z.Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer..Nat Genet2007;39:655-60

[30] Brown LA,Chin SF,Zayed AA.ESR1 gene amplification in breast cancer: a common phenomenon?.Nat Genet2008;40:806-7 PMCID:PMC2846830

[31] Horlings HM,Nordgard SH,Han W.ESR1 gene amplification in breast cancer: a common phenomenon?.Nat Genet2008;40:807-8

[32] Reis-Filho JS,Lambros MB,Johnson N.ESR1 gene amplification in breast cancer: a common phenomenon?.Nat Genet2008;40:809-10

[33] Vincent-Salomon A,Lucchesi C,Delattre O.ESR1 gene amplification in breast cancer: a common phenomenon?.Nat Genet2008;40:809

[34] Tsiambas E,Salemis N,Lambropoulou S.Significance of estrogen receptor 1 (ESR-1) gene imbalances in colon and hepatocellular carcinomas based on tissue microarrays analysis..Med Oncol2011;28:934-40

[35] Tomita S,Nakano M,Kawazoe T.Estrogen receptor alpha gene ESR1 amplification may predict endocrine therapy responsiveness in breast cancer patients..Cancer Sci2009;100:1012-7

[36] Moelans CB,Monsuur HN,van Diest PJ.Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes..Mod Pathol2010;23:1029-39

[37] Jeselsohn R,Buchwalter G,Meric-Bernstam F.Emergence of constitutively active estrogen receptor-alpha mutations in pretreated advanced estrogen receptor-positive breast cancer..Clin Cancer Res2014;20:1757-67 PMCID:PMC3998833

[38] Schiff R,Fu X.Abstract SY01-01: Endocrine resistance in metastatic breast cancer: Mechanisms and new therapeutic strategies.2018;Chicago, ILAACR Annual Meeting

[39] Basudan A,Hartmaier RJ,Bahreini A.Frequent ESR1 and CDK pathway copy-number alterations in metastatic breast cancer..Mol Cancer Res2019;17:457-68 PMCID:PMC6359977

[40] Markiewicz A,Skokowski J,Szade J.Prognostic significance of ESR1 amplification and ESR1 PvuII, CYP2C19*2, UGT2B15*2 polymorphisms in breast cancer patients..PLoS One2013;8:e72219 PMCID:PMC3738574

[41] Nielsen KV,Sven Müller,Birgitte B.Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer..Breast Cancer Res Treat2011;127:345-55

[42] Holst F.ESR1-amplification-associated estrogen receptor alpha activity in breast cancer..Trends Endocrinol Metab2016;27:751-2

[43] Khan SA,Khurana KK,Numann PJ.Estrogen receptor expression in benign breast epithelium and breast cancer risk..J Natl Cancer Inst1998;90:37-42

[44] Shoker BS,Sibson DR,Sloane JP.Oestrogen receptor expression in the normal and pre-cancerous breast..J Pathol1999;188:237-44

[45] Burkhardt L,Hermann I,Choschzick M.Gene amplification in ductal carcinoma in situ of the breast..Breast Cancer Res Treat2010;123:757-65

[46] Quenel-Tueux N,Rudewicz J,Pulido M.Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer..Br J Cancer2015;113:585-94 PMCID:PMC4647692

[47] Li S,Shao J,Liu W.Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts..Cell Rep2013;4:1116-30 PMCID:PMC3881975

[48] Aguilar H,Bonifaci N,Islam A.Biological reprogramming in acquired resistance to endocrine therapy of breast cancer..Oncogene2010;29:6071-83

[49] Haddow A,Paterson E.Influence of synthetic oestrogens on advanced malignant disease..Br Med J1944;2:393-8 PMCID:PMC2286289

[50] Kota K,Steffi Oesterreich.Estradiol as a targeted, late-line therapy in metastatic breast cancer with estrogen receptor amplification..Cureus2017;9:e1434 PMCID:PMC5587405

[51] Magnani L,Gadaleta RM,Fabris S.Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERalpha metastatic breast cancer..Nat Genet2017;49:444-50 PMCID:PMC5326683

[52] Weis KE,Thomas JA,Katzenellenbogen BS.Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein..Mol Endocrinol1996;10:1388-98

[53] Toy W,Won H,Sakr RA.ESR1 ligand-binding domain mutations in hormone-resistant breast cancer..Nat Genet2013;45:1439-45 PMCID:PMC3903423

[54] Merenbakh-Lamin K,Yeheskel A,Soussan-Gutman L.D538G mutation in estrogen receptor-alpha: a novel mechanism for acquired endocrine resistance in breast cancer..Cancer Res2013;73:6856-64

[55] Robinson DR,Vats P,Lonigro RJ.Activating ESR1 mutations in hormone-resistant metastatic breast cancer..Nat Genet2013;45:1446-51 PMCID:PMC4009946

[56] Chandarlapaty S,He W,Samoila A.Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the BOLERO-2 clinical trial..JAMA Oncol2016;2:1310-5 PMCID:PMC5063698

[57] Spoerke JM,Walter K,Wilson TR.Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant..Nat Commun2016;7:11579 PMCID:PMC4869259

[58] Schiavon G,Garcia-Murillas I,Pearson A.Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer..Sci Transl Med2015;7:313ra182 PMCID:PMC4998737

[59] Fribbens C,Kilburn L,Garcia-Murillas I.Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer..J Clin Oncol2016;34:2961-8

[60] Wang P,Gyanchandani R,Hartmaier RJ.Sensitive detection of mono-and polyclonal ESR1 mutations in primary tumors, metastatic lesions, and cell-free DNA of breast cancer patients..Clin Cancer Res2016;22:1130-7 PMCID:PMC4775406

[61] Gelsomino L,Rechoum Y,Pejerrey SM.Erratum to: ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling..Breast Cancer Res Treat2017;163:639-40

[62] Harrod A,Nguyen VTM,Ramos-Garcia L.Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer..Oncogene2017;36:2286-96 PMCID:PMC5245767

[63] Toy W,Razavi P,Goeppert AU.Activating ESR1 mutations differentially affect the efficacy of ER antagonists..Cancer Discov2017;7:277-87 PMCID:PMC5340622

[64] Jeselsohn R,Pun M,Liu W.Allele-specific chromatin recruitment and therapeutic vulnerabilities of ESR1 activating mutations..Cancer Cell2018;33:173-86.e5 PMCID:PMC5813700

[65] Shang Y,DiRenzo J,Brown M.Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription..Cell2000;103:843-52

[66] Gates LA,Chen Y,Lei JT.Proteomic profiling identifies key coactivators utilized by mutant ERalpha proteins as potential new therapeutic targets..Oncogene2018;37:4581-98 PMCID:PMC6095836

[67] Osborne CK.Mechanisms of endocrine resistance in breast cancer..Annu Rev Med2011;62:233-47 PMCID:PMC3656649

[68] Nagasawa J,Kahraman M,Bonnefous C.Identification of an orally bioavailable chromene-based selective estrogen receptor degrader (SERD) that demonstrates robust activity in a model of tamoxifen-resistant breast cancer..J Med Chem2018;61:7917-28

[69] Hamilton EP,Armstrong AC,Jhaveri K.A first-in-human study of the new oral selective estrogen receptor degrader AZD9496 for ER(+)/HER2(-) advanced breast cancer..Clin Cancer Res2018;24:3510-8

[70] Wardell SE,Alley HM,VanArsdale T.Efficacy of SERD/SERM Hybrid-CDK4/6 inhibitor combinations in models of endocrine therapy-resistant breast cancer..Clin Cancer Res2015;21:5121-30 PMCID:PMC4644714

[71] Turner NC,Verma S,Cristofanilli M.Palbociclib in hormone-receptor-positive advanced breast cancer..N Engl J Med2015;373:209-19

[72] Giltnane JM,Stricker TP,Young CD.Genomic profiling of ER(+) breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance..Sci Transl Med2017;9: PMCID:PMC5723145

[73] Veeraraghavan J,Cao XX,Wang X.Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers..Nat Commun2014;5:4577 PMCID:PMC4130357

[74] Dowsett M,Ebbs SR,Skene A.Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer..J Natl Cancer Inst2007;99:167-70

[75] Lei JT,Zhang J,Chan DW.Functional annotation of ESR1 gene fusions in estrogen receptor-positive breast cancer..Cell Rep2018;24:1434-44e7 PMCID:PMC6171747

[76] Adelson K,Sparano JA,Wright JJ.Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York cancer consortium trial..NPJ Breast Cancer2016;2:16037 PMCID:PMC5515340

[77] Hartmaier RJ,Priedigkeit N,Parachoniak CA.Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer..Ann Oncol2018;29:872-80 PMCID:PMC5913625

[78] Tomlins SA,Perner S,Mehra R.Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer..Science2005;310:644-8

[79] Mani RS,Callahan K,Nyati MK.Induced chromosomal proximity and gene fusions in prostate cancer..Science2009;326:1230 PMCID:PMC2935583

[80] Haffner MC,Toubaji A,Albadine R.Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements..Nat Genet2010;42:668-75 PMCID:PMC3157086

[81] Ju BG,Perissi V,Rose DW.A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription..Science2006;312:1798-802

[82] Carroll JS,Song J,Geistlinger TR.Genome-wide analysis of estrogen receptor binding sites..Nat Genet2006;38:1289-97